Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of Herba Patriniae (Patrinia villosa) and Coix seed (Coix lacryma-jobi) is a traditional Chinese medicine (TCM) formulation valued for its heat-clearing, phlegm-reducing, antipyretic, and diuretic properties. In TCM philosophy, this combination is used to address damp-heat stagnation and toxicity, which are considered pathogenic factors in diseases such as colorectal cancer. Preliminary studies suggest that the HC combination may have promising efficacy in the treatment of colorectal cancer by acting on multiple signaling pathways including phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR), p53, transforming growth factor-β/SMAD, NF-κB, and Wnt/β-catenin. The main active components include polysaccharides from Herba Patriniae and coixenolide/coixol from Coix seed[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on herba patriniae + coix seed.